[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yun Dai Chen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100572860","multicenter-real-world-cohort-study-evaluating-the-impact-of-early-intensive-lipid-lowering-therapy-on-the-prognosis-of-acute-coronary-syndrome-patientselite-acs-100572860",false,"NCT06738758","Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)","Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients","ELITE-ACS","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. This hospitalization for ACS, which includes ST-segment elevation MI (STEMI), non-ST-segment elevation MI (NSTEMI), or unstable angina pectoris (UA) with a GRACE score of intermediate to high risk.\n3. Written informed consent must be obtained from eligible patients prior to study enrollment.\n4. LDL-C ≥1.8 mmol\u002FL in patients using statin; LDL-C ≥2.6 mmol\u002FL in those not taking statin in the last 4 weeks.\n\nExclusion Criteria:\n\n1. Received PCSK9 inhibitor therapy within 3 months.\n2. Patient has any life-threatening severe disease, including severe liver injury and persistent elevation of serum transaminases, and severe renal failure.\n3. Patient has a history of renal or cardiac transplantation.\n4. The patient is a pregnant or breastfeeding woman or a woman planning to become pregnant.\n\nPatients judged by the investigator to be unsuitable for enrollment.","ALL","18 Years",{"count":20,"type":21},6000,"ESTIMATED","1 Year","OBSERVATIONAL","The purpose of this clinical trial is to evaluate the impact of early initiation of PCSK9 inhibitor therapy for intensive lipid-lowering in Chinese patients with acute coronary syndrome (ACS) during hospitalization on the rate of lipid goal attainment, the time to achieve guideline-recommended lipid levels within one year, and the incidence of adverse cardiovascular events.\n\nThe primary research question is whether early initiation of PCSK9 inhibitor therapy during hospitalization for ACS patients in a real-world Chinese setting can increase the rate of lipid goal attainment, shorten the time to reach guideline-recommended lipid levels within one year, and improve the risk of adverse cardiovascular events.\n\nResearchers will compare three lipid-lowering strategies: PCSK9 inhibitor therapy (with or without statins ± Ezetimibe\u002FHybutimibe), statin plus Ezetimibe\u002FHybutimibe therapy, and statin monotherapy, to assess the potential of PCSK9 inhibitor drugs in accelerating lipid goal achievement and reducing adverse cardiovascular events in ACS patients.\n\nParticipants will:\n\nReceive PCSK9 inhibitor therapy (with or without daily statins ± Ezetimibe\u002FHybutimibe) every two weeks, or daily statin plus Ezetimibe\u002FHybutimibe therapy, or daily statin monotherapy.\n\nUndergo follow-up assessments of relevant laboratory indicators at baseline, 3 days after admission, discharge, and 1, 3, 6, and 12 months post-discharge.\n\nRecord the occurrence of major adverse cardiovascular events.",[26],"Acute Coronary Syndromes",[26,28,29,30],"PCSK9 Inhibitor","Lipid compliance time and rate","First cardiovascular event","RECRUITING","2025-03-13",{"date":34,"type":35},"2025-03-17","ACTUAL",{"date":37,"type":35},"2024-12-16",{"date":39,"type":21},"2027-12-31",{"name":41,"class":42},"Yun Dai Chen","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100581762","assessing-coronary-non-culprit-plaque-early-with-start-of-pcsk9-inhibitors-in-acute-myocardial-infarction-access-ami-100581762","NCT06854523","Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI)","Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction","ACCESS-AMI","Inclusion Criteria:\n\n1. Age ≥18 years old.\n2. Admitted to hospital for acute myocardial infarction (STEMI, NSTEMI) and successfully underwent PCI of the infarct vessel.\n3. Coronary angiography revealed two non-infarct-related arteries with non-blocking lesions (diameter stenosis of 40-70%).\n4. Able to sign informed consent.\n5. Willing to undergo 1-year follow-up.\n\nExclusion Criteria:\n\n1. Left main artery disease or severe coronary artery calcification;\n2. Hemodynamic instability or uncontrolled arrhythmia;\n3. History of coronary artery bypass;\n4. severe renal insufficiency, active liver disease or liver insufficiency, hematological disease, metabolic or endocrine dysfunction, systemic infection, active malignant tumor and other potentially life-threatening diseases, or the expected survival time is \\\u003C 1 year;\n5. Received any PCSK9 inhibitor treatment within the previous 3 months;\n6. Pregnant or nursing women or women planning pregnancy;\n7. The researcher determined that it was not suitable for inclusion in the group.",{"count":53,"type":21},300,"INTERVENTIONAL",[56],"NA","This study is planned to start on January 2024.\n\nThe goal of this clinical trial is to learn whether the perioperative administration (within 24 hours before or after primary PCI) of PCSK9 inhibitors can ameliorate plaque progression and adverse outcomes in patients with acute myocardial infarction (AMI). The main questions it aims to answer are:\n\nCan perioperative PCSK9 inhibition improve the plaque stability and inflammation of perivascular adipose tissue (index of plaque attenuation（IPA ）and perivascular fat attenuation index（FAI）) of non-target lesions? Researchers will compare PCSK9 inhibitors with statin plus ezetimibe therapy to evaluate the potential of PCSK9 inhibitors in mitigating the progression of non-target lesion plaques and reducing adverse cardiovascular events in patients with AMI.\n\nParticipants will:\n\nTake PCSK9 inhibitors every two weeks or daily statin plus ezetimibe therapy. Conduct a follow-up examination with optical coherence tomography (OCT) or coronary computed tomography angiography (CTA) after 12 months.\n\nRecord the occurrence of major adverse cardiovascular events.",[59],"Acute Myocardial Infarction",[59,61,62,28],"Pericoronary artery fat attenuation index","Index of Plaque Attenuation","NOT_YET_RECRUITING","2025-02-25",{"date":66,"type":35},"2025-03-03",{"date":68,"type":21},"2025-04-15",{"date":70,"type":21},"2026-12-31",{"name":41,"class":42},2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":43},"100559690","retrospective-analysis-of-the-effect-of-in-hospital-initiation-of-pcsk9i-on-clinical-outcomes-in-chinese-acs-patients-100559690","NCT06567418","Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients","Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients: A Database-based Retrospective Analysis","Inclusion Criteria:\n\n* Patients diagnosed with Acute Coronary Syndrome (ACS) upon hospital admission.\n* Patients aged 18 years or older.\n* Patients who received Alirocumab 75 mg in combination with statin therapy ± Ezetimibe as the intervention group, and those treated exclusively with statin therapy ± Ezetimibe as the control group, either during hospitalization or at discharge.\n* Patients with at least one follow-up record.\n\nExclusion Criteria:\n\n* Patients who received Evolocumab treatment at any time.\n* Patients who received Inclisiran treatment at any time.",{"count":81,"type":21},10000,"The objective of this study is to investigate the effectiveness of in-hospital initiation of alirocumab combined with statin ± ezetimibe on major cardiovascular events (MACE) in Chinese ACS patients. The main question it aims to answer is:\n\nwhether early initiation PCKS9i in hospital could reduce recent cardiovascular event risk in Chinese ACS patients in real-world setting.\n\nData from CCA Database-Chest Pain Center were screened for all ACS patients from 01-Jan 2021 to 31-Dec 2023. Patients diagnosed with STEMI, NSTEMI or UA at admission were identified at the first step. Then, for intervention group, patients who received alirocumab 75mg combined with statin ± ezetimibe during the ACS hospitalization (including the discharge date) will be included; for control group, patients who received statin ± ezetimibe during the ACS hospitalization will be included. All enrolled patients were required to have at least one documented follow-up visit.",[84],"Acute Coronary Syndrome","2024-08-20",{"date":87,"type":35},"2024-08-22",{"date":89,"type":35},"2024-08-01",{"date":91,"type":21},"2025-01-31",{"name":41,"class":42},""]